Cargando…

Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study

AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (...

Descripción completa

Detalles Bibliográficos
Autores principales: Seco-Calvo, Jesús, Sánchez-Herráez, Sergio, Casis, Luis, Valdivia, Asier, Perez-Urzelai, Itxaro, Gil, Javier, Echevarría, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672324/
https://www.ncbi.nlm.nih.gov/pubmed/33174472
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2
_version_ 1783611109210587136
author Seco-Calvo, Jesús
Sánchez-Herráez, Sergio
Casis, Luis
Valdivia, Asier
Perez-Urzelai, Itxaro
Gil, Javier
Echevarría, Enrique
author_facet Seco-Calvo, Jesús
Sánchez-Herráez, Sergio
Casis, Luis
Valdivia, Asier
Perez-Urzelai, Itxaro
Gil, Javier
Echevarría, Enrique
author_sort Seco-Calvo, Jesús
collection PubMed
description AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (Ahlbäck grade ≥ 3 and clinical indications for arthrocentesis) recruited through the (Orthopaedic Department at the Complejo Asistencial Universitario de León, Spain (CAULE)), measuring synovial fluid levels of puromycin-sensitive aminopeptidase (PSA), neutral aminopeptidase (NAP), aminopeptidase B (APB), prolyl endopeptidase (PEP), aspartate aminopeptidase (ASP), glutamyl aminopeptidase (GLU) and pyroglutamyl aminopeptidase (PGAP). RESULTS: Synovial fluid peptidase activity varied significantly as a function of clinical signs, with differences in levels of PEP (p = 0.020), ASP (p < 0.001), and PGAP (p = 0. 003) associated with knee locking, PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p = 0.000) with knee failure, and PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p < 0.001) with knee effusion. Further, patients with the greatest functional impairment had significantly higher levels of APB (p = 0.005), PEP (p = 0.005), ASP (p = 0.006), GLU (p = 0.020), and PGAP (p < 0.001) activity, though not of NAP or PSA, indicating local alterations in the renin-angiotensin system. A binary logistic regression model showed that PSA was protective (p = 0.005; Exp (B) 0.949), whereas PEP (p = 0.005) and GLU were risk factors (p = 0.012). CONCLUSION: These results suggest synovial fluid peptidase activity could play a role as a measure of disease burden and predictive biomarker of progression in KOA. Cite this article: Bone Joint Res 2020;9(11):789–797.
format Online
Article
Text
id pubmed-7672324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Editorial Society of Bone & Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-76723242020-11-19 Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study Seco-Calvo, Jesús Sánchez-Herráez, Sergio Casis, Luis Valdivia, Asier Perez-Urzelai, Itxaro Gil, Javier Echevarría, Enrique Bone Joint Res Arthritis AIMS: To analyze the potential role of synovial fluid peptidase activity as a measure of disease burden and predictive biomarker of progression in knee osteoarthritis (KOA). METHODS: A cross-sectional study of 39 patients (women 71.8%, men 28.2%; mean age of 72.03 years (SD 1.15) with advanced KOA (Ahlbäck grade ≥ 3 and clinical indications for arthrocentesis) recruited through the (Orthopaedic Department at the Complejo Asistencial Universitario de León, Spain (CAULE)), measuring synovial fluid levels of puromycin-sensitive aminopeptidase (PSA), neutral aminopeptidase (NAP), aminopeptidase B (APB), prolyl endopeptidase (PEP), aspartate aminopeptidase (ASP), glutamyl aminopeptidase (GLU) and pyroglutamyl aminopeptidase (PGAP). RESULTS: Synovial fluid peptidase activity varied significantly as a function of clinical signs, with differences in levels of PEP (p = 0.020), ASP (p < 0.001), and PGAP (p = 0. 003) associated with knee locking, PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p = 0.000) with knee failure, and PEP (p = 0.006), ASP (p = 0.001), GLU (p = 0.037), and PGAP (p < 0.001) with knee effusion. Further, patients with the greatest functional impairment had significantly higher levels of APB (p = 0.005), PEP (p = 0.005), ASP (p = 0.006), GLU (p = 0.020), and PGAP (p < 0.001) activity, though not of NAP or PSA, indicating local alterations in the renin-angiotensin system. A binary logistic regression model showed that PSA was protective (p = 0.005; Exp (B) 0.949), whereas PEP (p = 0.005) and GLU were risk factors (p = 0.012). CONCLUSION: These results suggest synovial fluid peptidase activity could play a role as a measure of disease burden and predictive biomarker of progression in KOA. Cite this article: Bone Joint Res 2020;9(11):789–797. The British Editorial Society of Bone & Joint Surgery 2020-11-11 /pmc/articles/PMC7672324/ /pubmed/33174472 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2 Text en © 2020 Author(s) et al. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Arthritis
Seco-Calvo, Jesús
Sánchez-Herráez, Sergio
Casis, Luis
Valdivia, Asier
Perez-Urzelai, Itxaro
Gil, Javier
Echevarría, Enrique
Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title_full Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title_fullStr Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title_full_unstemmed Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title_short Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
title_sort synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression: a cross-sectional study
topic Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672324/
https://www.ncbi.nlm.nih.gov/pubmed/33174472
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0022.R2
work_keys_str_mv AT secocalvojesus synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT sanchezherraezsergio synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT casisluis synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT valdiviaasier synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT perezurzelaiitxaro synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT giljavier synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy
AT echevarriaenrique synovialfluidpeptidaseactivityasabiomarkerforkneeosteoarthritisclinicalprogressionacrosssectionalstudy